Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2024 ASCO Annual Meeting will be a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care, highlighting the latest innovations in cancer research and education. We're excited to bring you the latest updates in oncology live from Chicago, IL. Stay tuned for expert interviews, podcasts, roundtable discussions, and more..
View all videos

ASCO 2024

31 May–04 June 2024 | Chicago, IL

🎥@ErikaHamilton9 of @SarahCannonDocs presents updated findings from DESTINY-Breast03 trial comparing T-DXd vs. T-DM1 in HER2+ metastatic #BreastCancer. Clinically meaningful improvement in OS, PFS, and PFS2 with T-DXd:

➡️⬅️

@ASCO @OncoAlert #BCSM #ASCO24

Image for twitter card

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Ph...

ow.ly

Join us for our Post-ASCO 2024 Highlights 📣

Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦

REGISTER & view the agendas 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/

#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1

Load More

ASCO 2024

31 May–04 June 2024 | Chicago, IL
The 2024 ASCO Annual Meeting will be a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care, highlighting the latest innovations in cancer research and education. We're excited to bring you the latest updates in oncology live from Chicago, IL. Stay tuned for expert interviews, podcasts, roundtable discussions, and more..
View all videos

🎥@ErikaHamilton9 of @SarahCannonDocs presents updated findings from DESTINY-Breast03 trial comparing T-DXd vs. T-DM1 in HER2+ metastatic #BreastCancer. Clinically meaningful improvement in OS, PFS, and PFS2 with T-DXd:

➡️⬅️

@ASCO @OncoAlert #BCSM #ASCO24

Image for twitter card

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

Erika Hamilton, MD, from the Sarah Cannon Research Institute in Nashville, TN, presents updated findings from the Ph...

ow.ly

Join us for our Post-ASCO 2024 Highlights 📣

Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦

REGISTER & view the agendas 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/

#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1

Load More